Literature DB >> 20218911

High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia.

Rahul Naithani1, M Mahapatra, Rajat Kumar, Pravas Mishra, Renu Saxena.   

Abstract

Oral high dose dexamethasone (HDD) was given as a single daily dose for four consecutive days, every 14 days for four courses. Twenty-nine patients were enrolled. Overall 20 patients (69%) responded: complete response (CR) was achieved in 16 (55%) patients, partial response (PR) in three (10%) patients and MR in one (3%) patient. In acute immune thrombocytopenic purpura (ITP) response rates after the first, second, third and fourth cycles were as follows: 64% (9/14), 64% (9/14), 79% (11/14), and 85.7% (12/14), respectively. In chronic ITP, overall response rates after the first, second, third and fourth cycles were as follows: 33% (5/15), 40% (6/15), 53% (8/15) and 53% (8/15) respectively. The median time to response was 14 days (4-42 days). Twelve out of 20 patients (5/12 acute ITP and 7/8 chronic ITP) relapsed; median relapse free survival till last follow-up in the remaining eight patients was 130 days (65-365 days).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218911     DOI: 10.3109/09537101003637257

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  3 in total

1.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

2.  Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.

Authors:  James B Bussel; Christina S Lee; Caroline Seery; Allison A Imahiyerobo; Michaela V Thompson; Diane Catellier; Ithamar G Turenne; Vivek L Patel; Paul A Basciano; Rebecca L Elstrom; Waleed Ghanima
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

Review 3.  Understanding Immune Thrombocytopenia: Looking Out of the Box.

Authors:  Alexandra Schifferli; Franco Cavalli; Bertrand Godeau; Howard A Liebman; Mike Recher; Paul Imbach; Thomas Kühne
Journal:  Front Med (Lausanne)       Date:  2021-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.